TABLE 2.
Percentage of patients that showed improvement or resolution of symptoms after 3 months from the initial evaluation
| Symptoms | With mesalamine treatment, No. of patients (%) | Without mesalamine treatment, No. of patients (%) | Statistical significance, P |
|---|---|---|---|
| Fussiness | 30/41 (73.17%) | 2/19 (10.52%) | 0.0001 |
| Spitting up/vomiting | 32/44 (72.72%) | 2/21 (9.5%) | 0.0001 |
| Changes on stool consistency* | 23/44 (52.27%) | 1/18 (5.2%) | 0.0005 |
| Decreased appetite/refusal to eat | 19/24 (79.16%) | 1/8 (12.5%) | 0.0016 |
| Respiratory problems† | 23/26 (88.46%) | 4/10 (40%) | 0.0062 |
| Choking/gagging | 31/38 (81.57%) | 5/13 (38.46%) | 0.0106 |
| Gassiness | 15/29 (51.72%) | 0/8 (0%) | 0.0121 |
| Back arching | 22/23 (95.65%) | 6/10 (60%) | 0.0214 |
| Skin problems‡ | 10/44 (58.82%) | 4/8 (50%) | 1.0000 |
| Hiccups | 30/31 (96.77%) | 9/11 (81.81%) | 0.1629 |
| Sleeping difficulties | 11/13 (84.61%) | 0/2 (0%) | 0.0571 |
| Visible blood or mucous in stool | 30/37 (81%) | 5/7 (71.42%) | 0.6188 |
*Watery or hard stools.
†Symptoms of persistent cough and congestion not related to another pathology.
‡Symptoms of atopic dermatitis and xerosis cutis.